RxDoctor Payments Data

Mary Throndson

Psychiatric/Mental Health · Clinton, LANPI 1528411196

Payments from drug & device makers

$3,194in general payments, 2019–2025

Across 197 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$749
  • AbbVie$481
  • Otsuka America Pharmaceutical, Inc.$383
  • Vanda Pharmaceuticals Inc.$247
  • Axsome Therapeutics, Inc.$232
  • Supernus Pharmaceuticals, Inc.$193
  • plus $910 from 18 others

What the payments were for

  • Food & beverage$3,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,194 in reported general payments places this provider in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate21$34,279
VraylarCariprazine Hcl25$33,680
RexultiBrexpiprazole18$24,805
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl28$5,274
Lurasidone Hcl15$4,852
VyvanseLisdexamfetamine Dimesylate13$4,221
Aripiprazole44$4,115
Trazodone Hcl135$1,468
Hydroxyzine Pamoate59$1,146
Clozapine18$1,076
Bupropion XlBupropion Hcl74$980
Duloxetine Hcl41$834
Buspirone Hcl38$817
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$777
Quetiapine Fumarate45$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$749$34,27921 claims
AbbVieVraylar$481$33,68025 claims
Otsuka America Pharmaceutical, Inc.Rexulti$383$24,80518 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$33$4,22113 claims
Lilly USA, LLCOlanzapine$20$23419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Clinton

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →